23/06/2026
Obesity is now widely understood as a complex chronic disease, and for many patients, achieving sustained and meaningful weight loss continues to present a significant challenge.
What makes this area particularly compelling is that our understanding of appetite regulation, metabolism and energy balance has advanced considerably over recent decades. As a result, new pharmacological therapies are changing what may be possible for patients living with obesity.
In this episode of Everyday Medicine, I’m joined by gastroenterologist Dr Matthew Peverelle to discuss the science behind modern weight loss medications, including GLP-1 receptor agonists and newer dual incretin therapies, and what clinicians should understand about their benefits, limitations and future potential.
We explore:
– How incretin-based therapies influence appetite, satiety and weight regulation
– The differences between GLP-1 receptor agonists and dual incretin therapies
– The effectiveness, risks and practical challenges of current treatments
– Where obesity pharmacotherapy may be heading in the years ahead
If you’re a clinician, or simply interested in the rapidly evolving field of obesity medicine, this is a fascinating and highly relevant conversation.
🎧 Listen to the episode here: https://www.gihealth.com.au/everyday-medicine-podcast/episode-190-pharmacological-treatments-for-obesity-with-dr-matthew-peverelle
As always, I’d welcome your reflections after listening.
Australians who are either overweight or obese are increasingly turning to pharmacological approaches, coupled with dietary measures, to achieve their weight loss goals before considering bariatric surgery. These therapies are typically considered for adults whose BMIs are equal to or abo